Background: Allergic contact dermatitis (ACD) is associated with increased production of cytokines. The patch test is the “gold-standard” diagnostic method, but it poses a risk of false results. Objective: To evaluate a novel laboratory technique, the Luminex LiquiChip, which simultaneously measures blood levels of multiple cytokines, as a diagnostic tool in patients with chrome-induced ACD. Methods: The study group included 20 patients with ACD and relevant patch test results for potassium dichromate and 19 patients with ACD for nickel or fragrance as control. Peripheral blood mononuclear cells (PBMCs) were cultured in the presence and absence of potassium dichromate. The Luminex LiquiChip was used to measure levels of the following cytokines: granulocyte-macrophage colony-stimulating factor, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, interferon-γ, and tumor necrosis factor (TNF)-α. Results: Potassium dichromate-stimulated PBMCs secreted significantly higher amounts of all cytokines except TNF-α than nonstimulated PBMCs. PBMCs from patients with ACD to chromium secreted significantly higher amounts of all cytokines tested, except IL-4, compared to PBMCs from patients with ACD to nickel or fragrance. Conclusions: Potassium dichromate stimulates the production of both Th1- and Th2-type cytokines in patients with chrome allergy. The Luminex LiquiChip is a promising in vitro method and may serve as a diagnostic tool for ACD.

1.
Shenefelt PD: Descripteve epidemiology of contact dermatitis in a university population. Am J Contact Dermat 1996;7:88-93.
2.
Johansen JD, Aalto-Korte K, Agner T, et al: European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis 2015;73:195-221.
3.
Kligman AM: A personal critique of diagnostic patch testing. Dermatology 1996;14:35-40.
4.
Schaeffer AC, Andersen KE, Bindslev-Jensen C, Mortz CG: The reproducibility of nickel, cobalt and chromate sensitization in patients tested at least twice in the period 1992-2014 with TRUE Test®. Contact Dermatitis 2016;75:111-113.
5.
Young HA, Hardy KJ: The role of interferon gamma in immune cell regulation. J Leukoc Biol 1995;58:373.
6.
Popple A, Williams J, Maxwell G, Gellatly N, Dearman RJ, Kimber I: The lymphocyte transformation test in allergic contact dermatitis: new opportunities. J Immunotoxicol 2016;13:84-91.
7.
Livni E, Lapidoth M, Halevy S: In vitro release of interferon-gamma and macrophage migration inhibition factor in drug induced urticaria and angioedema. Acta Derm Venereol 1999;79:18-22.
8.
Trattner A, Akerman L, Lapidoth M, Klein T, Weiss H, Ben Chaim B, David M: Use of in vitro release of interferon gamma in the diagnosis of contact allergy to potassium dichromate - a controlled study. Contact Dermatitis 2003;49:191-193.
9.
Kapsenberg ML, Wierenga EA, Stiekema FE, et al: Th1 lymphokine production profile of nickel-specific CD4+ T-lymphocytes clones from nickel contact allergic and non-allergic individuals. J Invest Dermatol 1992:98:59-63.
10.
Lim D, Kim MK, Jang YP, Kim J: Sceptridium ternatum attenuates allergic contact dermatitis-like skin lesions by inhibiting T helper 2-type immune responses and inflammatory responses in a mouse model. J Dermatol Sci 2015;79:288-297.
11.
Otsuka A, Kabashima K: Contribution of basophils to cutaneous immune reactions and Th2-mediated allergic responses. Front Immunol 2015;6:393.
12.
Sugita K, Nomura T, Ikenouchi-Sugita A, Ito T, Nakamura M, Miyachi Y, Tokura Y, Kabashima K: Influence of Th2 cells on hair cycle/growth after repeated cutaneous application of hapten. Clin Exp Dermatol 2014;39:213-215.
13.
Carson RT, Vignali DAA: Simultaneous quantification of 15 cytokines using a multiplex flow cytometric assay. J Immunol Methods 1999;227:41-52.
14.
Szodoray P, Alex P, Brun JG, Centola M, Jonsson R: Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004:59:592-599.
15.
Finner H: Stepwise multiple test procedures and control of directional errors. Ann Statist 1999;27:274-289.
16.
Abramson JH: WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Perspect Innov 2011;8:1.
17.
Rothman KJ, Greenland S: Modern Epidemiology, ed 2. Philadelphia, Lippincott Williams & Wilkins, 1998.
18.
Sinigaglia F, Scheidegger D, Garotta G, Scheper R, Pletscher M, Lanzavecchia A: Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis. J Immunol 1985;135:3929-3932.
19.
Van den Broeke L, Graslund A, Larsson PH, Nilsson JL, Wahlberg JE, Scheynius A, Karlberg AT: Free radicals as potential mediators of metal allergy: effect of ascorbic acid on lymphocyte proliferation and IFN-γ production in contact allergy Ni2+ and Co2+. Acta Derm Venereol 1998;78:95-98.
20.
Borg L, Christensen JM, Kristensen J, Nielsen NH, Menne T, Poulsen LK: Nickel-induced cytokine production from mononuclear cells in nickel-sensitive individuals and controls. Arch Dermatol Res 2000;292:285-291.
21.
Minang JT, Areström I, Zuber B, Jönsson G, Troye-Blomberg M, Ahlborg N: Nickel-induced IL-10 down-regulates Th1- but not Th2-type cytokine responses to the contact allergen nickel. Clin Exp Immunol 2006; 143:494-502.
22.
Kitagaki H, Watanabe K, Shiohara T: Repeated elicitation of contact hypersensitivity (CS) induces a shift in local cytokine expression from Th1 to Th-type profile. J Invest Dermatol 1996:106:825-832.
23.
Spiewak R, Moed H, von Blomberg BM, Bruynzeel DP, Scheper RJ, Gibbs S, Rustemeyer T: Allergic contact dermatitis to nickel: modified in vitro test protocols for better detection of allergen-specific response. Contact Dermatitis 2007;56:63-69.
24.
Wang BJ, Shiao JS, Chen CJ, Lee YC, Guo YL: Tumour necrotizing factor-alpha promoter and GST-T1 genotype predict skin allergy to chromate in cement workers in Taiwan. Contact Dermatitis 2007;57:309-315.
25.
Yoshihisa Y, Rehman MU, Yamakoshi-Shibutani T, Shimizu T: In vitro effects of zinc on the cytokine production from peripheral blood mononuclear cells in patients with zinc allergy. Springerplus 2015;4:404.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.